IGF1 and metabolic dysfunction-associated steatotic liver disease: An increasing body of research indicates that IGF1 directly targets the liver, as well as hepatocytes, macrophages, and hematopoietic stem cells, through a variety of mechanisms that inhibit the progression of nonalcoholic fatty liver disease (72).